Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules
- PMID: 1646112
- DOI: 10.1002/eji.1830210602
Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules
Abstract
Mice that were intranasally immunized with different influenza A virus hemagglutinins (HA), derived from PR8 (H1N1), A/Yamagata (H1N1) or A/Fukuoka (H3N2) virus, together with cholera toxin B subunit as an adjuvant, were examined for protection against PR8 infection; PR8 HA and A/Yamagata HA immunization conferred complete protection, while A/Fukuoka HA immunization failed to confer protection. In parallel with protection, PR8 HA-, A/Yamagata HA-, and A/Fukuoka HA-immunized mice produced a high, a moderate and a low level of PR8 HA-reactive IgA in the respiratory tract, respectively. These IgA antibodies were not only higher in content in the nasal secretions, but also more cross-reactive than IgG. The purified IgA antibodies from respiratory tract washings of PR8 HA-immunized mice, which contained the HA-specific IgA corresponding to the amount detected in the nasal wash, were able to protect mice from PR8 challenge when transferred to the respiratory tract of naive mice. The transfer of IgA from A/Yamagata HA-immunized mice also afforded cross-protection against PR8 infection, whereas the IgA from A/Fukuoka HA-immunized mice failed to provide protection. The ability of transferred IgA to prevent viral infection was dependent on the amount of HA-reactive IgA remaining in the respiratory tract of the host at the time of infection. These experiments directly demonstrate that IgA antibodies to influenza A virus HA by themselves play a pivotal role in defence not only against homologous virus infection, but also against heterologous drift virus infection at the respiratory mucosa, the portal of entry for the viruses.
Similar articles
-
Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine.Eur J Immunol. 1992 Feb;22(2):477-81. doi: 10.1002/eji.1830220228. Eur J Immunol. 1992. PMID: 1537382
-
Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit.J Immunol. 1992 Aug 1;149(3):981-8. J Immunol. 1992. PMID: 1634780
-
Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant.J Med Virol. 2005 Jan;75(1):130-6. doi: 10.1002/jmv.20247. J Med Virol. 2005. PMID: 15543590
-
Studies on the usefulness of intranasal inactivated influenza vaccines.Vaccine. 2010 Aug 31;28(38):6393-7. doi: 10.1016/j.vaccine.2010.05.019. Epub 2010 May 20. Vaccine. 2010. PMID: 20493820 Review.
-
Defense mechanisms against influenza virus infection in the respiratory tract mucosa.Jpn J Infect Dis. 2004 Dec;57(6):236-47. Jpn J Infect Dis. 2004. PMID: 15623947 Review.
Cited by
-
Differential localization and function of antibody-forming cells responsive to inactivated or live-attenuated influenza virus vaccines.Int Immunol. 2013 Mar;25(3):183-95. doi: 10.1093/intimm/dxs107. Epub 2012 Nov 8. Int Immunol. 2013. PMID: 23143476 Free PMC article.
-
Intranasal immunization with a formalin-inactivated human influenza A virus whole-virion vaccine alone and intranasal immunization with a split-virion vaccine with mucosal adjuvants show similar levels of cross-protection.Clin Vaccine Immunol. 2012 Jul;19(7):979-90. doi: 10.1128/CVI.00016-12. Epub 2012 May 2. Clin Vaccine Immunol. 2012. PMID: 22552600 Free PMC article.
-
Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology.Vaccine. 2022 Sep 29;40(41):5892-5903. doi: 10.1016/j.vaccine.2022.08.049. Epub 2022 Aug 26. Vaccine. 2022. PMID: 36064667 Free PMC article.
-
Elastase-dependent live attenuated swine influenza A viruses are immunogenic and confer protection against swine influenza A virus infection in pigs.J Virol. 2009 Oct;83(19):10198-210. doi: 10.1128/JVI.00926-09. Epub 2009 Jul 22. J Virol. 2009. PMID: 19625412 Free PMC article.
-
Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine.Vaccine. 2012 Nov 6;30(48):6871-7. doi: 10.1016/j.vaccine.2012.09.007. Epub 2012 Sep 16. Vaccine. 2012. PMID: 22989689 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous